The University of Virginia is conducting a clinical research study for adults ages 18 and over, who fall into one of the following groups:
o Group A (cutaneous/subcutaneous) will include the following tumor-specific cohorts:
? Squamous cell carcinomas of the head and neck (SCCHN)
? Dermatological
? Genitourinary/gynecological
? Gastrointestinal
? Other cutaneous/subcutaneously accessible solid tumors
o Group B: visceral lesions accessible by ultrasound/CT guidance
The goal of this study is to determine at what dose the study treatment (ASP9801) is safe and tolerated in study participants with cancer who have tumors that cannot be removed (unresectable) or have spread (metastasized) to a different part of the body. This will be done by enrolling small groups of participants to receive different doses of the study treatment, starting with a very small dose and gradually increasing. The dose amount you receive will depend on the group you are assigned to. When the best tolerated dose is identified, it will be used to evaluate if the treatment causes tumors to shrink in participants.
You will be in the study for roughly 29 weeks (or about 6.5 months). This includes about 4 weeks for screening, 8 weeks of treatment, and 17 weeks of follow up. You may be on treatment longer, if your doctor deems you are receiving benefit. So the length of time you are in the study, and total number of visits, will depend on how you respond to the treatment.
Reimbursement: Up to $175 per night for a hotel
Study-related procedures that are being done beyond your standard of care will be provided at no cost to you or your insurance.
Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT03954067
Compensation: $50 per completed visit